Last reviewed · How we verify
Prednisolone, prednisone, or methylprednisolone
Prednisolone, prednisone, or methylprednisolone is a Corticosteroid (glucocorticoid) Small molecule drug developed by Children's Hospital of Philadelphia. It is currently FDA-approved for Inflammatory and autoimmune disorders (rheumatoid arthritis, lupus, vasculitis), Allergic and asthmatic conditions, Hematologic malignancies (as part of combination chemotherapy). Also known as: Prednisolone, prednisone, methylprednisolone.
Corticosteroids that suppress the immune system and reduce inflammation by binding to glucocorticoid receptors and inhibiting pro-inflammatory cytokine production.
Corticosteroids that suppress the immune system and reduce inflammation by binding to glucocorticoid receptors and inhibiting pro-inflammatory cytokine production. Used for Inflammatory and autoimmune disorders (rheumatoid arthritis, lupus, vasculitis), Allergic and asthmatic conditions, Hematologic malignancies (as part of combination chemotherapy).
At a glance
| Generic name | Prednisolone, prednisone, or methylprednisolone |
|---|---|
| Also known as | Prednisolone, prednisone, methylprednisolone |
| Sponsor | Children's Hospital of Philadelphia |
| Drug class | Corticosteroid (glucocorticoid) |
| Target | Glucocorticoid receptor (GR) |
| Modality | Small molecule |
| Therapeutic area | Immunology, Rheumatology, Endocrinology, Oncology (supportive care) |
| Phase | FDA-approved |
Mechanism of action
These systemic corticosteroids work by entering cells and binding to intracellular glucocorticoid receptors, which then translocate to the nucleus and modulate gene expression. This leads to decreased production of inflammatory mediators (cytokines, chemokines, adhesion molecules) and suppression of immune cell activation and proliferation. They are used across multiple therapeutic areas due to their broad anti-inflammatory and immunosuppressive effects.
Approved indications
- Inflammatory and autoimmune disorders (rheumatoid arthritis, lupus, vasculitis)
- Allergic and asthmatic conditions
- Hematologic malignancies (as part of combination chemotherapy)
- Adrenal insufficiency
- Organ transplant rejection prophylaxis
- Severe infections with systemic inflammation
Common side effects
- Immunosuppression / increased infection risk
- Hyperglycemia / diabetes exacerbation
- Osteoporosis / bone loss
- Hypertension
- Mood changes / psychiatric effects
- Cushingoid features (with chronic use)
- Gastrointestinal upset
- Insomnia
Key clinical trials
- Short-term Steroid Therapy in Patients With P. Jirovecii Pneumonia Due to HIV / AIDS (NA)
- Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma (PHASE3)
- A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001) (PHASE3)
- Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia (PHASE2)
- A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia (PHASE3)
- Brentuximab Vedotin and Combination Chemotherapy in Treating Children and Young Adults With Stage IIB, Stage IIIB, IVA, or IVB Hodgkin Lymphoma (PHASE3)
- Combination Chemotherapy With or Without Donor Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia (PHASE2)
- A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Prednisolone, prednisone, or methylprednisolone CI brief — competitive landscape report
- Prednisolone, prednisone, or methylprednisolone updates RSS · CI watch RSS
- Children's Hospital of Philadelphia portfolio CI
Frequently asked questions about Prednisolone, prednisone, or methylprednisolone
What is Prednisolone, prednisone, or methylprednisolone?
How does Prednisolone, prednisone, or methylprednisolone work?
What is Prednisolone, prednisone, or methylprednisolone used for?
Who makes Prednisolone, prednisone, or methylprednisolone?
Is Prednisolone, prednisone, or methylprednisolone also known as anything else?
What drug class is Prednisolone, prednisone, or methylprednisolone in?
What development phase is Prednisolone, prednisone, or methylprednisolone in?
What are the side effects of Prednisolone, prednisone, or methylprednisolone?
What does Prednisolone, prednisone, or methylprednisolone target?
Related
- Drug class: All Corticosteroid (glucocorticoid) drugs
- Target: All drugs targeting Glucocorticoid receptor (GR)
- Manufacturer: Children's Hospital of Philadelphia — full pipeline
- Therapeutic area: All drugs in Immunology, Rheumatology, Endocrinology, Oncology (supportive care)
- Indication: Drugs for Inflammatory and autoimmune disorders (rheumatoid arthritis, lupus, vasculitis)
- Indication: Drugs for Allergic and asthmatic conditions
- Indication: Drugs for Hematologic malignancies (as part of combination chemotherapy)
- Also known as: Prednisolone, prednisone, methylprednisolone
- Compare: Prednisolone, prednisone, or methylprednisolone vs similar drugs
- Pricing: Prednisolone, prednisone, or methylprednisolone cost, discount & access